|
Synonyms: BMS-224818 | LEA29Y | Nulojix®
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class:
Peptide
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids. 
View more information in the IUPHAR Pharmacology Education Project: belatacept |
| No information available. |
Summary of Clinical Use  |
| Approved for prophylaxis of organ rejection after kidney transplant. The first analysis of long-term outcomes (7 years post-transplant) for belatacept-induced immunosuppression compared to cyclosporine treatment are reported by Vincenti et al. (2016) [2]. These results, from clinical trial NCT00256750, show a clear and significant benefit from treating with belatacept rather than cyclosporine. The authors suggest that the improvement is likely due to the alternative mechanism of action of belatacept (blocks T-cell costimulation) and its non-nephrotoxic nature, in comparison to cyclosporine which is often the cause of failure of transplanted kidneys over time. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Binding of belatacept to CD80/86 (on antigen presenting cells) provides a negative feedback mechanism which results in T-cell deactivation and immunosuppression. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
